MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

For the past four decades, psilocybin research has focused on one area: the treatment of mental health disorders, including depression, anxiety, existential distress associated with serious medical illnesses, post-traumatic stress disorder, and addiction.

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Bristol Myers Squibb on Sept. 8 announced positive phase II results from the registrational QUINTESSENTIAL trial (NCT06297226) of arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM).

September 18, 2026

Vol.52 No.34

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

Change swept through executive offices at cancer centers in recent weeks, shifting top leadership at the University of Texas MD Anderson Cancer Center, Duke Cancer Institute, and the University of Florida.

MD Anderson names 2026 Andrew Sabin Family Fellows

The University of Texas MD Anderson Cancer Center has announced the 2026 class of Andrew Sabin Family Fellows, marking 102 fellows funded through this philanthropic investment that provides support for emerging scientists and clinicians making discoveries in cancer research and patient care.

September 11, 2026

Vol.52 No.33

MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

YOU MAY BE INTERESTED IN

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

MD Anderson names 2026 Andrew Sabin Family Fellows

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

YOU MAY BE INTERESTED IN

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy“Because it works in one neural system, you begin to wonder: Well, what about another?”

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centersLee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

MD Anderson names 2026 Andrew Sabin Family Fellows

Never miss an issue!

Login

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida